OXIMIO Canada Achieves Medical Device Establishment License (MDEL)
Oximio is pleased to announce that Oximio BARL Canada has officially obtained its Medical Device Establishment License (MDEL), effective December 2025. While BARL previously held an MDEL, this newly issued licence reflects our transition to operating under the Oximio Business Centre (OBC) structure and reinforces the continuity of our long-standing compliance.
Securing the updated MDEL formally authorizes Oximio to import, distribute, and store medical devices, further strengthening our service offering and expanding the range of solutions we can provide. The licence plays a vital role in ensuring the safety and quality of medical products in Canada by confirming that licence holders comply with rigorous regulatory requirements, including complaint handling, recall management, and incident reporting.
Kaitlin Guarasci, Managing Director of Oximio, Canada, commented on the achievement:
“This is a significant achievement as it further enhances our credibility, broadening the services we can provide to customers.”
This accomplishment reflects Oximio’s ongoing commitment to excellence, regulatory compliance, and delivering trusted solutions to the healthcare sector.
For further information on our supply chain solutions for clinical trials across Canada and North America, please visit our North America solutions page or contact us.
